# Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

> **NCT04869943** · PHASE3 · TERMINATED · sponsor: **Veru Inc.** · enrollment: 52 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Enobosarm
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT04869943
- **Lead sponsor:** Veru Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-12
- **Primary completion:** 2024-01-09
- **Final completion:** 2024-01-09
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2024-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04869943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04869943, "Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04869943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*